Gabriella Fontanini
University of Pisa · 602 works · 19,865 citations · h-index 69
Top works
- Relation of neovascularisation to metastasis of non-small-cell lung cancer
- Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
- Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
- Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma.
- Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer
- Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A
- The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer
- Angiogenesis as a Prognostic Indicator of Survival in Non-Small-Cell Lung Carcinoma: a Prospective Study
- Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
- Microvessel count predicts metastatic disease and survival in non‐small cell lung cancer
- Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
- Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
- Angiogenesis: An indicator of metastasis in non-small cell lung cancer invading the thoracic inlet
- Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype
- Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer